P53 Mutation and LOH at Chromosome 9 in Urothelial Carcinoma

被引:0
|
作者
Beothe, Tamas [2 ,3 ]
Nagy, Anetta [2 ]
Farkas, Laszlo [3 ]
Kovacs, Gyula [1 ,2 ]
机构
[1] Univ Pecs, Sch Med, Dept Lab Med, H-7624 Pecs, Hungary
[2] Univ Heidelberg, Fac Med, Heidelberg, Germany
[3] Univ Pecs, Sch Med, Dept Urol, H-7624 Pecs, Hungary
关键词
Urothelial carcinoma; chromosome 17p LOH; p53; mutation; chromosome; 9; LOH; developmental pathway; TRANSITIONAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; BLADDER-CANCER; IDENTIFIES PTPRD; URINARY-BLADDER; HYPERMETHYLATION; PROGRESSION; KINASE; GLIOBLASTOMA; ASSOCIATION;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Mutation of the p.5.3 gene has been implicated in the development of carcinoma in situ (CIS) to invasive solid urothelial carcinomas (UC) whereas loss of heterozygosity (LOH) at chromosome 9 has been suggested to plag part in the development of papillary UCs. Patients and Methods: The p53 mutation and LOH at chromosomes 17p13.1 and 9 were analysed in 120 UCs. Tumor and matched normal DNA were used for microsatellite allelotyping of chromosome 17p and the entire chromosome 9. Results: LOH at 17p13.1 was found in each grade and stage of the UCs, but mutation of the p53 occurred only in the highly malignant G3 tumors including papillary pT1G3 UCs. LOH were found at one or more of the seven tumor suppressor gene loci along chromosome 9 in all but two of the UCs with p53 mutation. Conclusion: Mutation of the p53 gene is not a pathway correlated genetic change, but is associated with the increased cell proliferation of G3 UCs.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 50 条
  • [1] P53 evaluation in urothelial bladder carcinoma
    Goupou, E.
    Moustakas, G.
    Nikolaidou, A.
    Manoloutsiou, I. Michalopoulou
    Klampatsas, A.
    Sarakapinas, G.
    Dimasis, N.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 345 - 345
  • [2] The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma
    Borowczak, Jedrzej
    Szczerbowski, Krzysztof
    Maniewski, Mateusz
    Zdrenka, Marek
    Slupski, Piotr
    Andrusewicz, Hanna
    Lysik-Miskurka, Joanna
    Rutkiewicz, Paula
    Bodnar, Magdalena
    Szylberg, Lukasz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (03): : 830 - 840
  • [3] The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma
    Jędrzej Borowczak
    Krzysztof Szczerbowski
    Mateusz Maniewski
    Marek Zdrenka
    Piotr Słupski
    Hanna Andrusewicz
    Joanna Łysik-Miśkurka
    Paula Rutkiewicz
    Magdalena Bodnar
    Łukasz Szylberg
    Clinical and Translational Oncology, 2023, 25 : 830 - 840
  • [5] OVEREXPRESSION AND MUTATION OF P53 IN ENDOMETRIAL CARCINOMA
    KOHLER, MF
    BERCHUCK, A
    DAVIDOFF, AM
    HUMPHREY, PA
    DODGE, RK
    IGLEHART, JD
    SOPER, JT
    CLARKEPEARSON, DL
    BAST, RC
    MARKS, JR
    CANCER RESEARCH, 1992, 52 (06) : 1622 - 1627
  • [6] p53 gene mutation in colorectal carcinoma
    Roa, JC
    Roa, I
    Melo, A
    Araya, JC
    Villaseca, MA
    Flores, M
    Schneider, B
    REVISTA MEDICA DE CHILE, 2000, 128 (09) : 996 - 1004
  • [7] P53 MUTATION IN HEPATOCELLULAR-CARCINOMA
    MIHM, S
    LEONHARDT, U
    RAMADORI, G
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1993, 31 (09): : 498 - 499
  • [8] p53 gene mutation in thyroid carcinoma
    Ho, YS
    Tseng, SC
    Chin, TY
    Hsieh, LL
    Lin, JD
    CANCER LETTERS, 1996, 103 (01) : 57 - 63
  • [9] LOH of p53 in congenital sacrococcygeal teratomas
    Kruslin, B
    Gall-Troselj, K
    Cizmic, A
    Turcic, M
    Belicza, M
    LABORATORY INVESTIGATION, 2002, 82 (01) : 312A - 312A
  • [10] Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis
    Hartmann, A
    Rösner, U
    Schlake, G
    Dietmaier, G
    Zaak, D
    Hofstaedter, F
    Knuechel, R
    LABORATORY INVESTIGATION, 2000, 80 (05) : 709 - 718